NCT05795348 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Fernandez J, Zhang J, Heidlauf T, Sartori M, Besier T, Rohrle O, Lloyd D
Multiscale musculoskeletal modelling, data-model fusion and electromyography-informed modelling. Interface Focus. 2016 Apr 6;6(2):20150084. doi: 10.1098/rsfs.2015.0084.
Hermens HJ, Freriks B, Disselhorst-Klug C, Rau G
Development of recommendations for SEMG sensors and sensor placement procedures. J Electromyogr Kinesiol. 2000 Oct;10(5):361-74. doi: 10.1016/s1050-6411(00)00027-4.
Manini TM, Clark BC
Dynapenia and aging: an update. J Gerontol A Biol Sci Med Sci. 2012 Jan;67(1):28-40. doi: 10.1093/gerona/glr010. Epub 2011 Mar 28.
O'Brien TD, Reeves ND, Baltzopoulos V, Jones DA, Maganaris CN
The effects of agonist and antagonist muscle activation on the knee extension moment-angle relationship in adults and children. Eur J Appl Physiol. 2009 Aug;106(6):849-56. doi: 10.1007/s00421-009-1088-4. Epub 2009 May 27.
Petterson SC, Barrance P, Buchanan T, Binder-Macleod S, Snyder-Mackler L
Mechanisms underlying quadriceps weakness in knee osteoarthritis. Med Sci Sports Exerc. 2008 Mar;40(3):422-7. doi: 10.1249/MSS.0b013e31815ef285.
Pons C, Borotikar B, Garetier M, Burdin V, Ben Salem D, Lempereur M, Brochard S
Quantifying skeletal muscle volume and shape in humans using MRI: A systematic review of validity and reliability. PLoS One. 2018 Nov 29;13(11):e0207847. doi: 10.1371/journal.pone.0207847. eCollection 2018.
Rice DA, McNair PJ
Quadriceps arthrogenic muscle inhibition: neural mechanisms and treatment perspectives. Semin Arthritis Rheum. 2010 Dec;40(3):250-66. doi: 10.1016/j.semarthrit.2009.10.001. Epub 2009 Dec 2.

ForceLoss: Part II - Osteoarthritic Patients. Development and Validation of Methods to Generate Personalised Models for the Differential Diagnosis of the Loss of Muscle Force

Details for clinical trial NCT05795348

Clinical trial NCT05795348 - References